A Decade+ Investment Pays off with Parkinson’s Biomarker Discovery
In 2010, the Michael J. Fox Foundation made a BIG bet on investing in researching a biomarker for Parkinson’s Disease (PPMI project). On April 12th it was announced that the bet paid off.
Researchers announced that with the α-synuclein seeding amplification assay (αSyn-SAA), they now have a tool capable of detecting abnormal alpha-synuclein, a key pathology in Parkinson’s disease (PD). The breakthrough marks a significant shift in understanding, diagnosing, and treating PD. The assay was validated with 93% accuracy and promises to enable earlier diagnoses, targeted treatments, and more efficient drug development. Efforts are underway to develop αSyn-SAA for the widespread use and optimize it to measure the amount of alpha-synuclein present, potentially through blood draws or nasal swabs. This development holds tremendous potential for transforming research and care for those living with Parkinson’s disease.
Nonprofit praises automatic expungement program that aims to help millions | FOX 17 Donations Decline for the First Time Since 2012, Fundraising Effectiveness Project Data Shows | NonProfit PRO These startups and nonprofits are keeping the abortion pill accessible | Fast Company
Sponsored: Looking for trusted nonprofit consultants in New York – or California? Nonprofit.ist has you covered.
Podcast: Play in new window | Download
NonprofitNewsfeed.com Summary of hundreds of news sources.